本帖最后由 老马 于 2012-1-13 21:20 编辑
( A& E: n, e; y, ~
- H6 g; A0 I( k- ~ B: ^1 o; @爱必妥和阿瓦斯丁的比较& U( i# o* E, t) m8 A& \0 E( Z
( C5 A9 n0 s! \" O$ Yhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
/ X! O7 j% \8 R1 p
( t4 G4 \$ k4 j4 M/ h: i1 P! C
1 C+ A; y* K, Y, c% G/ Uhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
, l6 b8 s& R" q% p/ A+ D5 N6 v- \==================================================9 l2 l$ `' g1 J& A% s5 n, U
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
: Y* r( A$ E1 P: y0 n5 O% y, s& rPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.: J) P" B# e8 y' a" o
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.: ]( J+ W- s- X2 l. p0 Y
|